Surgery Partners, Inc.
SGRYHealthcareNASDAQMedical Care Facilities · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSurgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. Valued at $2.06B, SGRY is a mid-cap name in its sector. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Market Cap
$2.06B
Beta
1.91
P/E (TTM)
—
P/E (Fwd)
56.25
EPS (TTM)
$-0.69
EPS (Fwd)
$0.28
ROE
2.3%
ROA
3.7%
Cash
$216.7M
Total Debt
$4.07B
Free CF
$183.6M
52W Change
-30.9%
Annual Financials
Cash vs Debt
Where SGRY stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, SGRY finished 4.07% above its 150-day moving average ($14.25) and 2.63% above its 200-day moving average ($14.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGRY overbought or oversold?
At the October 15, 2026 close, SGRY's RSI(14) was 58.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $216.7M in cash, though total debt stands at $4.07B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $183.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 2.3% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.54B (2022) to $3.31B (2025), reflecting a 30% increase over the period.
A beta of 1.91 means SGRY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Surgery Partners, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SGRY.